Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05918640
Other study ID # 23-020814
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 27, 2023
Est. completion date July 30, 2028

Study information

Verified date June 2024
Source Children's Hospital of Philadelphia
Contact Theodore Laetsch, MD
Phone 267-425-5544
Email LAETSCHT@chop.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.


Description:

In this study, the investigators will test the activity of lurbinectedin as a targeted therapy for FET (FUS, Ewing Sarcoma Breakpoint Region 1 (EWRS1), TATA-Box-Binding Protein Associated Factor 15 (TAF15)). Ewing sarcoma is driven by the Ewing Sarcoma-Friend Leukemia Integration 1 Transcription Factor (EWS-FLI1). Lurbinectedin has been shown to inhibit EWS-FLI1 and Ewing Sarcoma-Wilms' Tumor Gene 1 (EWS-WT1) in preclinical models. Therefore, the goal of this study is to see if Lurbinectedin can be used to inhibit EWS-FLI1, EWS-WT1, or other FET fusion proteins to drive tumor responses in patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date July 30, 2028
Est. primary completion date July 30, 2026
Accepts healthy volunteers No
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: 1. Age = 10 years. 2. Phase 1: Histological confirmed diagnosis of recurrent or relapsed solid tumor failing primary therapy. Patients must have a known FET fusion (fusion that contains EWSR1, FUS, or TAF15) as documented by next generation sequencing, polymerase chain reaction (PCR) or Fluorescence in situ hybridization (FISH). Patients with a histological diagnosis of Ewing sarcoma with EWS-FLI1 are eligible for dose escalation but not for the exploratory cohort. Please note patients with Ewing sarcoma and alternative FET-ETS fusions (including but not limited to EWS-ERG, EWS-ETV1, EWS-ETV4, EWS-FEV, FUS-ERG, FUS-FEV) are eligible for the exploratory cohort. 3. Phase 2: Histologically confirmed diagnosis of recurrent or relapsed Ewing sarcoma failing primary therapy with confirmation of EWS-FLI1 fusion and breakpoint by Next generation sequencing or PCR or EWSR1 rearrangement confirmed by FISH and available tissue for central confirmation of EWS-FLI1 fusion and breakpoint. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age =16 years) or Lansky of at least 60 (age <16 years). 5. Disease status (baseline imaging must be performed within 28 days of Day 1 of study treatment): At least one site of measurable disease on CT or MRI as defined by RECIST 1.1 OR evaluable disease with at least one site of disease that has not been previously radiated. 6. Meets organ function requirements as outlined below: 1. Liver: Alanine aminotransferase (ALT) = 2.5X upper limit of normal. For the purposes of this study the upper limit of normal for ALT is 45 U/L. Aspartate aminotransferase (AST) = 2.5X upper limit of normal. For the purposes of this study the upper limit of normal for AST is 50 U/L. Total bilirubin = 1.5X institutional upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin <3X institutional upper limit of normal. 2. Renal: Creatinine Calculated creatinine clearance (by the Schwartz equation for patients <18 years of age and Cockroft-Gault formula (Appendix B) for patients =18 years of age) or radionuclide glomerular filtration rate (GFR) = 50 mL/min /m2 or a serum creatinine less than or equal to the age/gender valued below: Age Maximum Serum Creatinine (mg/dL) Male Female 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 = 16 years 1.7 1.4 3. Bone marrow: Absolute Neutrophil Count (ANC) = 1,000/µL (>one week since last dose of short acting medications (e.g. filgrastim) and > two weeks since last dose of long acting medications (e.g. peg-filgrastim)) Platelet Count (PLTs) = 100,000/ µL (>two weeks since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days of screening laboratories) Patients with a history of bone marrow involvement are required to have bilateral bone marrow aspirates and biopsies at baseline. Subjects with bone marrow disease are eligible as long as they meet the hematologic requirements above and are not known to be refractory to red cell or platelet transfusions. 4. Cardiac: Creatine phosphokinase = 2.5 x institutional upper limit of normal, Left ventricular ejection fraction (LVEF) or shortening fraction (SF) per institutional norm LVEF > 50% OR SF >28%. 7. Written, voluntary informed consent 8. Fertile males and females of childbearing potential must agree to use an effective method of birth control from screening, through Day 1 of study and for 6 months after last study drug administration for females and 4 months for males. Women of childbearing potential must have a negative pregnancy test during screening procedures. Effective methods of birth control include: double barrier method (condom, diaphragm), abstinence, an intrauterine device (IUD), levonorgestrol implants, medroxyprogesterone acetate injections, or oral contraception. For those subjects whose preferred and usual lifestyle employs abstinence, refraining from heterosexual intercourse must be practiced during the entire active phase of the trial. 9. Patients =18 years must be willing to undergo tumor biopsy at study entry. Patients with Ewing sarcoma or DSRCT must be willing to undergo biopsy post-treatment. If biopsy is contraindicated, enrollment must be approved by study PI and archival tissue must be available. 10. Time elapsed from previous therapy: 1. Must be = 3 weeks for systemic myelosuppressive therapy 2. = 2 weeks for local radiation therapy (small field), = 150 days after thyrotropin binding inhibition (TBI), craniospinal external beam radiotherapy (XRT) or radiation to =50% of the pelvis 3. = 2 weeks for major surgery 4. = 2 weeks for monoclonal antibodies and oral kinase inhibitors. 5. = 6 weeks for autologous stem cell transplant. 6 months for allogeneic stem cell transplant. 6. = 6 weeks for any type of cellular therapy 11. Patients must be recovered to baseline or Grade =1from the acute adverse effects of prior treatments, with the exception of alopecia and decreased deep tendon reflexes. Exclusion Criteria: 1. Prior therapy with trabectedin or lurbinectedin. 2. Subjects with known brain metastases. 3. Subjects with a known bleeding diathesis. 4. Subjects who are pregnant or breastfeeding. 5. Concurrent therapy: 1. Patients who are currently receiving an investigational drug or another anticancer agent 2. Patients receiving over the counter or herbal supplement with significant potential hepatotoxicity in the opinion of the investigator. 3. Patients receiving a medically necessary strong or moderate CYP3A4 inhibitor or inducer within 14 days prior to the first dose of study drug. 6. Clinically significant, unrelated illness or uncontrolled infection which would, in the opinion of the treating physician, compromise the patient's ability to tolerate the investigational agents or be likely to interfere with the study procedures or results. 7. Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded. 8. Patients with known active viral hepatitis (i.e. Hepatitis A, B, or C)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lurbinectedin
Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States National Institutes of Health Clinical Center Bethesda Maryland
United States Dana-Farber Cancer Institute Boston Massachusetts
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States Cedars-Sinai Medical Center Los Angeles California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia Jazz Pharmaceuticals, Stand Up To Cancer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Dose Limiting Toxicities (DLTs) First cycle (approximately 21 days) Dose Limiting Toxicities (DLTs) will be evaluated. within 28 days of the first dose
Primary Phase 1: Frequency of adverse events Adverse events to be reported during treatment and for at least 28 days after last dose. 28 days after last dose
Primary Phase 1: Complete Response or Partial Response Percentage of participants with complete response or partial response will be assessed approximately every 2 to 4 cycles through the end of treatment and up to at least 28 days after the last dose. through the end of treatment, an average of 1 year
Primary Phase 2: Event-Free Survival (EFS) Event-free survival (EFS) is based on investigator assessment from baseline until Month 24. 2 years
Secondary Phase 1: Maximum observed Plasma Concentration (Cmax) Maximum observed plasma concentration (Cmax) will be used to assess Lurbinectedin Pharmacokinetics at the end of cycle 1 (each cycle is 28 days)
Secondary Phase 1: Area under the concentration-time curve (AUC) Area under the concentration-time curve (AUC) will be used to assess Lurbinectedin Pharmacokinetics at the end of cycle 1 (each cycle is 28 days)
Secondary Phase 2: 6-month Progression Free Survival (PFS) Progression Free Survival (PFS) assessed from the first dose of study drug to earliest date of death or progressive disease. 6 months
Secondary Phase 1: Duration of Response (DoR) Duration of Response (DoR) defined as time from date of first response (Complete Response or Partial Response) in responders to date of progression or death Up to 5 years
Secondary Phase 2: Overall Survival Overall survival (OS) defined as the time from enrollment to date of death due to any cause. Up to 5 years
Secondary Phase 2: Disease Control Rate Disease Control ate is defined as the percentage of patients who sustain a complete response, partial response, or stable disease over 5 years. Up to 5 Years
See also
  Status Clinical Trial Phase
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Withdrawn NCT04719416 - Relaxation Therapy in Pediatric Oncology N/A
Completed NCT01645436 - Physical Activity in Pediatric Cancer (PAPEC) N/A
Completed NCT04409301 - Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05425043 - Granulocyte Transfusions After Umbilical Cord Blood Transplant N/A
Recruiting NCT05071859 - Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting NCT03241251 - Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Recruiting NCT05569512 - Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Phase 1/Phase 2
Enrolling by invitation NCT05294380 - Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
Completed NCT02665819 - Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility. N/A
Completed NCT02675166 - Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
Not yet recruiting NCT05454163 - Post-radiotherapy Rhinosinusitis in Children
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Withdrawn NCT01828502 - Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer Phase 2
Completed NCT02032121 - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors N/A
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1